On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Novo Nordisk took an early step towards genome editing with yesterday’s Bluebird tie-up, and isn’t ruling out a move into conventional gene therapies.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.
Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.